Pharmasset Announces Clevudine And R7128 Presentations At HEP DART
Dec 15th 2007Drug InformationClinical Trials
Pharmasset, Inc. (Nasdaq: VRUS) announces that interim results of physician-sponsored studies of clevudine for the treatment of chronic hepatitis B virus (HBV) and both preclinical and clinical results of R7128 for the treatment of chronic hepatitis C virus (HCV) will be presented at the Frontiers in Drug Development in Viral Hepatitis (HEP-DART) conference being held in Lahaina, Hawaii from December 9 - 13, 2007. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
